Co-morbidities Prevention & Management, References

References Part IV - Prevention & Management of Co-morbidities

Specific References


2. European Smoking Cessation Guidelines (

3. Calvo-Sanchez M et al. HIV Med 2015; 16: 201-210


5. ESC/EAC Guidelines for the Management of Dyslipidaemias Eur Heart J September 2019

6. EHS 2013 Guidelines. J. Hypertens; 2013:7:1281-1357

7. ESC/ESH guidelines for the management of arterial hypertension EHJ. 2018 Sep 1;39(33):3021-3104

8. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. 2005

9. American Diabetes association. Standards of Medical Care in Diabetes-2017 Abridged for Primary Care Providers Clin Diabetes. 2017 Jan;35(1):5-26


11. Swanepoel CR, Atta MG, D’Agati et al. Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference Kidney Int. 2018 Mar;93(3):545-559

12. Mocroft et al. for the D:A:D study. PLoS Med. 2015 Mar 31;12(3)

13. Scherzer R et al. for the VA cohort. AIDS.2014 Jun 1;28(9):1289-95

14. Cai J, Osikowicz M, Sebastiani G. Clinical significance of elevated liver transaminases in HIV-infected patients. AIDS 2019 Jul 1;33(8):1267-1282

15. Roberto de Franchis on behalf of the Baveno VI Faculty. Expanding consensus in portal hypertension Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 2015 63(3):743–752

16. Portal Hypertensive Bleeding inCirrhosis: Risk Stratification, Diagnosis, and Management: 2016 PracticeGuidance by the American Association for the Study of Liver Diseases Hepatology. 2017 Jan;65(1):310-335

17. Maurice JB et al. AIDS 2017; 31:1621-32

18. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease European Association for the Study of the Liver (EASL),European Association for the Study of Diabetes (EASD) European Association for the Study of Obesity (EASO). J Hepa- tol. 2016 Jun;64(6):1388-402

19. Cohen MS, Chen YQ, McAuley M et al. Antiretroviral Therapy for the Prevention of HIV-1 Transmission N Engl J Med 2016; 375:830-839

20. Rodger AJ, Cambiano V, Bruun T et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet 2019; 393: 2428–38

21. Kooij KW et al. HIV infection is independently associated with frailty in middle-aged HIV type 1-infected individuals compared with similar but uninfected controls. AIDS. 2016 Jan;30(2):241-50

22. Fried LP, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56:M146–56

23. Searle SD, et al. A standard procedure for creating a frailty index. BMC Geriatr 2008; 8:24

24. Koroukian SM, Schiltz N, Warner DF, Sun J, Bakaki PM, Smyth KA, et al. Combinations of chronic conditions, functional limitations, and geriatric syndromes that predict health outcomes. J Gen Intern Med 2016; 31:630–637

25. Dent E, et all. The Asia-Pacific Clinical Practice Guidelines for the Management of Frailty. J Am Med Dir Assoc. 2017 Jul 1;18(7):564-575

26. Theou O. et al Reversing Frailty Levels in Primary Care Using the CARES Model. Can Geriatr J. 2017 Sep; 20(3): 105–111

27. Eron JJ Jr, Lelievre JD, Kalayjian R et al. Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial. Lancet HIV 2018 Dec 13. S2352-3018(18)30296-0. doi: 10.1016/S2352-3018(18)30296-0

28. Michienzi SM, Schriever CA and Badowski ME. Abacavir/lamivudine/dolutegravir single tablet regimen in patients with human immunodeficiency virus and end-stage renal disease on hemodialysis. Int J STD AIDS 2019 doi: 10.1177/0956462418800865

General References

Peters B, Post F, Wierzbicki AS et al. Screening for chronic co-morbid disease in people with HIV: the need for a strategic approach. HIV Med. 2013 Jan;14 Suppl 1:1-11

El-Sadr WM, Lundgren JD, Neaton JD et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006,355:2283-2296

Silverberg MJ, Chao C, Leyden WA et al. HIV infection and the risk of cancers with and without a known infectious cause. AIDS. 2009 Nov 13;23(17):2337-45

Clifford GM, Polesel J, Rickenbach M et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005 Mar 16;97(6):425-32

De Wit S, Sabin CA, Weber R et al. Incidence and risk factors for new onset diabetes mellitus in HIV infected patients: the D:A:D study. Diabetes care 2008 Jun;31(6):1224-9

Tien PC, Schneider MF, Cox C et al. Association of HIV infection with incident diabetes mellitus: impact of using hemoglobin A1C as a criterion for diabetes. J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):334-40

Freiberg MS, Chang CC, Kuller LH et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013 Apr 22;173(8):614-22

Mollan KR, Smurzynski M, Eron JJ, et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data.
Ann Intern Med. 2014 Jul 1;161(1):1-10

Worm SW, Sabin S, Weber R et al. Risk of Myocardial Infarction in Patientswith HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. J Infect Dis. 2010 Feb 1;201(3):318-30

Triant VA, Lee H, Hadigan C et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immuno-deficiency virus disease. J Clin Endocrinol Metab 2007,92:2506-2512

Islam FM, Wu J, Jansson et al. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med. 2012 Sep;13(8):453-68

Grunfeld C, Delaney JA, Wanke C et al. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurement from the FRAM study. AIDS. 2009 Sep 10;23(14):1841-9

Friis-Moeller N, Thibébaut R, Reiss P et al. for the D:A:D study group. Predicting the risk of cardiovascular disease in HIV-infected patients: the Data Collection on Adverse Effects of Anti-HIV Drugs Study. Eur J Cardiovasc Prev Rehabil. 2010 Oct;17(5):491-501

Rothman MS, Bessesen MT. HIV infection and osteoporosis: patho-phys-iology, diagnosis and treatment options. Curr Osteoporos Rep. 2012 Dec;10(4):270-7

Ryom L, Mocroft A, Kirk O et al. on behalf of the D:A:D study group. Association Between Antiretroviral Exposure and Renal Impairment Among HIV-positive Persons with Normal Baseline Renal Function: the D:A:D study. J Infect Dis. 2013 May;207(9):1359-1369

Alsauskas ZC, Medapalli RK, Ross MJ. Expert opinion on pharmacotherapy of kidney disease in HIV-infected patients. Expert Opin Pharmacother 2011,12:691-704

J Hepatol. 2016 Jun;64(6):1388-402. doi: 10.1016/j.jhep.2015.11.004. Epub 2016 Apr 7

Agüero F, Forner A, Manzardo C et al. Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular
carcinoma . Hepatology. 2016 Feb;63(2):488-98

Jose M Miro, Torre-Cisnero J, Moreno et al. AGESIDA/GESITRA-SEIMC, PNS and ONT consensus document on solid organ transplant (SOT) in HIV-infected patients in Spain. Enferm Infecc Microbiol Clin. 2005 Jun-Jul;23(6):353-62

Van Maarseveen EM, Rogers CC, Trofe-Clark J, et al. Drug-drug interactions between antiretroviral and immunosuppressive agents in HIV-infected patients after solid organ transplantation: a review. AIDS Patient Care STDS. 2012 Oct;26(10):568-81

Mazuecos A, Fernandez A, Andres A, et al .Spanish Study Group Advances in Renal Transplantation (GREAT). Kidney transplantation outcomes in HIV infection: the European experience. Am J Transplant. 2011 Mar;11(3):635-6

Stock PG, Barin B, Murphy B et al.Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med. 2010 Nov 18;363(21):2004-14. Erra-tum in: N Engl J Med. 2011 Mar 7;364(11):1082

Mocroft A, Kirk O, Reiss P et al. for the EuroSIDA Study Group. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010 Jul 17;24(11):1667-78

Bonjoch A, Bayes B, Riba J, et al. Validation of estimated renal function measurements compared with the isotopic glomerular filtration rate in an HIV-infected cohort. Antiviral Res 2010,88:347-354

Chang HR, Pella PM. Atazanavir urolithiasis. N Engl J Med 2006,355:2158-2159

Gaspar G, Monereo A, Garcia-Reyne A et al. Fanconi syndrome and acute renal failure in a patient treated with tenofovir: a call for caution. AIDS 2004,18:351-352

Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005,40:1559-1585

Benhamou Y, Di Martino V, Bochet M et al. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001,34:283-287

Kovari H, Ledergerber B, Peter U et al. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis 2009,49:626-635

Weber R, Sabin CA, Friis-Moeller N et al. Liver related deaths in persons infected with the human immunodeficiency virus: The D:A:D study. Arch Intern. Med 2006 Aug 14-28;166(15):1632-1641

Qurishi N, Kreutzberg C, Lüchters G et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003 Nov 22;362(9397):1708-13 ageing-and-aged-care/wellbeing-and-participation/healthy-ageing/falls- prevention/falls-prevention-tools